Contineum Therapeutics, Inc. Class A Common Stock reported earnings of -$ 0.49 per CTNM share on Nov 3, 2026, beating analysts' expectations by
| Report Date | Nov 3, 2026 |
|---|---|
| Forecasted EPS | -$ 0.45 |
| Earnings Per Share (Surprise) | -$ 0.49 (-$ 0.04) |
| Last Year's EPS | -$ 0.54 |
| EPS YoY Change |
Out of the last 17 earnings reporting periods, Contineum Therapeutics, Inc. Class A Common Stock beat analysts’ expectations 5 times and fell short of expectations 6 time(s). Contineum Therapeutics, Inc. Class A Common Stock reported earnings per share of -$ 0.49 in the last report falling to reach an estimated EPS of -$ 0.45 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 3, 2026 | -$ 0.45 | -$ 0.49 | -$ 0.45 | |
| Jul 30, 2026 | -$ 0.45 | -$ 0.40 | -$ 0.62 | |
| May 5, 2026 | -$ 0.55 | -$ 0.39 | -$ 0.62 | |
| Mar 5, 2026 | -$ 0.50 | -$ 0.49 | -$ 0.56 | |
| Oct 30, 2025 | -$ 0.58 | -$ 0.45 | -$ 0.40 | |
| Aug 5, 2025 | -$ 0.56 | -$ 0.62 | -$ 0.39 | |
| May 14, 2025 | -$ 0.56 | -$ 0.62 | -$ 3.55 | |
| Mar 6, 2025 | -$ 0.44 | -$ 0.56 | -$ 1.44 | |
| Nov 6, 2024 | -$ 0.41 | -$ 0.40 | -$ 0.31 | |
| Aug 13, 2024 | -$ 0.35 | -$ 0.39 | -$ 0.25 | |
| May 16, 2024 | -$ 0.46 | -$ 3.55 | $ 1.62 | |
| Mar 15, 2024 | - | -$ 1.44 | -$ 0.19 | |
| Dec 31, 2023 | - | -$ 0.31 | -$ 0.30 | |
| Sep 30, 2023 | - | -$ 0.25 | - | - |
| Jun 30, 2023 | - | $ 1.62 | - | - |
| Mar 31, 2023 | - | -$ 0.19 | - | - |
| Dec 31, 2022 | - | -$ 0.30 | - | - |
Contineum Therapeutics, Inc. Class A Common Stock’s stock was trading at $ 9.56 on Nov 2, 2026 a day before the last earnings report was released.Following the release of the earnings report, CTNM’s price increased to $ 9.79 on Nov 4, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 3, 2026 | -$ 0.49 | $ 9.56 | $ 9.79 | |
| Jul 30, 2026 | -$ 0.40 | $ 14.38 | $ 15.49 | |
| May 5, 2026 | -$ 0.39 | $ 14.15 | $ 14.94 | |
| Mar 5, 2026 | -$ 0.49 | $ 14.86 | $ 13.88 | |
| Oct 30, 2025 | -$ 0.45 | $ 10.90 | $ 11.01 | |
| Aug 5, 2025 | -$ 0.62 | $ 5.80 | $ 6.33 | |
| May 14, 2025 | -$ 0.62 | $ 3.81 | $ 3.94 | |
| Mar 6, 2025 | -$ 0.56 | $ 6.10 | $ 6.77 | |
| Nov 6, 2024 | -$ 0.40 | $ 16.60 | $ 18.55 | |
| Aug 13, 2024 | -$ 0.39 | $ 17.32 | $ 17.28 | |
| May 16, 2024 | -$ 3.55 | $ 15.31 | $ 15.50 |
Contineum Therapeutics, Inc. Class A Common Stock released its most recent earnings reports in November 2026, July 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Contineum Therapeutics, Inc. Class A Common Stock missed analysts’ expectations during the last earnings period by
